These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 18161149)

  • 21. Denosumab (prolia) for postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2010 Oct; 52(1349):81-2. PubMed ID: 21045756
    [No Abstract]   [Full Text] [Related]  

  • 22. Recent insights into the biology of bone turnover.
    Riches PL; Ralston SH
    J R Coll Physicians Edinb; 2010 Mar; 40(1):66-9. PubMed ID: 21125043
    [No Abstract]   [Full Text] [Related]  

  • 23. The sledgehammer.
    Prescrire Int; 2011 Jun; 20(117):144. PubMed ID: 21678699
    [No Abstract]   [Full Text] [Related]  

  • 24. The long and the short of bone therapy.
    Whyte MP
    N Engl J Med; 2006 Feb; 354(8):860-3. PubMed ID: 16495400
    [No Abstract]   [Full Text] [Related]  

  • 25. Denosumab in postmenopausal women with low bone mineral density.
    McClung MR; Lewiecki EM; Cohen SB; Bolognese MA; Woodson GC; Moffett AH; Peacock M; Miller PD; Lederman SN; Chesnut CH; Lain D; Kivitz AJ; Holloway DL; Zhang C; Peterson MC; Bekker PJ;
    N Engl J Med; 2006 Feb; 354(8):821-31. PubMed ID: 16495394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Denosumab for treatment of postmenopausal osteoporosis].
    Syversen U; Halse JI; Geisler J; Eriksen EF
    Tidsskr Nor Laegeforen; 2011 Oct; 131(19):1893-6. PubMed ID: 21984295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of RANKL: a new approach to the treatment of osteoporosis.
    Doggrell SA
    Expert Opin Pharmacother; 2006 Jun; 7(8):1097-100. PubMed ID: 16722819
    [No Abstract]   [Full Text] [Related]  

  • 28. [Myeloma bone disease and RANKL signaling].
    Abe M
    Clin Calcium; 2011 Aug; 21(8):1167-74. PubMed ID: 21814021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging treatments for postmenopausal osteoporosis - focus on denosumab.
    Geusens P
    Clin Interv Aging; 2009; 4():241-50. PubMed ID: 19554095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Involvement of RANKL/RANK pathway in bone metastasis in breast cancer].
    Yoneda T
    Clin Calcium; 2011 Aug; 21(8):1159-66. PubMed ID: 21814020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Denosumab, osteoporosis, and prevention of fractures.
    Blythe SL
    N Engl J Med; 2009 Nov; 361(22):2189-90; author reply 2190-1. PubMed ID: 19950410
    [No Abstract]   [Full Text] [Related]  

  • 32. [Denosumab efficient against osteoporosis. A biological drug gives new possibilities to treat a public disease].
    Törring O
    Lakartidningen; 2010 Mar 3-9; 107(9):574-5. PubMed ID: 20387753
    [No Abstract]   [Full Text] [Related]  

  • 33. [New bone density conservation agents for osteoporosis under research and development: PTH (1-34)].
    Endo I; Matsumoto T
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():443-6. PubMed ID: 18161146
    [No Abstract]   [Full Text] [Related]  

  • 34. [Therapeutic agents for disorders of bone and calcium metabolism--Denosumab, a fully human monoclocal antibody-targeting RANKL as a therapy for cancer-induced bone diseases].
    Mera K; Ito K
    Clin Calcium; 2007 Jan; 17(1):37-46. PubMed ID: 17211092
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Denosumab and bisphosphonates: different mechanisms of action and effects.
    Baron R; Ferrari S; Russell RG
    Bone; 2011 Apr; 48(4):677-92. PubMed ID: 21145999
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Expectation for alleviation of joint destruction in rheumatoid arthritis by new molecular targeting pharmaceutics including anti-rankle antibody].
    Nakamura T
    Clin Calcium; 2009 Mar; 19(3):381-6. PubMed ID: 19252248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advances in bone biology and new treatments for bone loss.
    Gallagher JC
    Maturitas; 2008 May; 60(1):65-9. PubMed ID: 18555623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Denosumab, osteoporosis, and prevention of fractures.
    Blackwood J
    N Engl J Med; 2009 Nov; 361(22):2189; author reply 2190-1. PubMed ID: 19950411
    [No Abstract]   [Full Text] [Related]  

  • 39. [Denosumab, the rheumatologist's joker?].
    Bérengère AR
    Rev Med Suisse; 2009 Jan; 5(185):59-62. PubMed ID: 19216327
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Anti-RANKL antibody for the treatment of rheumatoid arthritis].
    Tanaka Y
    Clin Calcium; 2011 Aug; 21(8):1223-9. PubMed ID: 21814029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.